| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Mupirocin lithium specifically targets bacterial isoleucyl-tRNA synthetase, an enzyme essential for protein synthesis. By reversibly inhibiting this enzyme, the compound blocks the incorporation of isoleucine into bacterial proteins, leading to inhibition of protein and RNA synthesis. At lower concentrations, it has bacteriostatic characteristics, while at higher concentrations it is bactericidal.
|
|---|---|
| ln Vitro |
In vitro, Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). It is also active against Methicillin-resistant Staphylococcus aureus (MRSA), Lactobacilli, Lactococci, Streptococci, and Leuconostocs. Its mechanism of action involves reversible inhibition of isoleucyl-tRNA synthetase.
|
| ln Vivo |
In vivo, Mupirocin lithium is an orally active antibiotic. It is used to treat bacterial infections, particularly those caused by Gram-positive organisms. Its activity against MRSA makes it a valuable tool for studying antibiotic resistance.
|
| Enzyme Assay |
The antimicrobial activity of Mupirocin lithium is assessed using standard microbiological assays, such as broth microdilution or agar diffusion, to determine the minimum inhibitory concentration (MIC) against various bacterial strains. Its mechanism of action is confirmed by evaluating its effect on protein synthesis in bacterial cells.
|
| Cell Assay |
Cellular assays for Mupirocin lithium involve treating bacterial cultures with the compound and measuring bacterial growth inhibition. The compound's effect on protein synthesis can be assessed by measuring the incorporation of radiolabeled amino acids into bacterial proteins.
|
| Animal Protocol |
In vivo studies of Mupirocin lithium are conducted in animal models of bacterial infection. The compound is administered orally, and its efficacy is evaluated by monitoring bacterial load, survival, and clinical signs of infection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mupirocin lithium are not extensively detailed in publicly available sources. As an orally active antibiotic, it is absorbed and distributed to target tissues.
|
| Toxicity/Toxicokinetics |
Mupirocin lithium is intended for research use only and is not for therapeutic or diagnostic use in humans. Its toxicological profile would be evaluated in preclinical studies.
|
| References |
[1]. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8.
[2]. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70. [3]. Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5. |
| Additional Infomation |
Mupirocin lithium is the lithium salt of the orally active antibiotic mupirocin, which inhibits bacterial isoleucyl-tRNA synthetase. It is a valuable tool for studying bacterial protein synthesis and antibiotic resistance.
|
| Molecular Formula |
C26H43LIO9
|
|---|---|
| Molecular Weight |
506.56
|
| Exact Mass |
500.299
|
| CAS # |
73346-79-9
|
| Related CAS # |
Mupirocin;12650-69-0;Mupirocin calcium;104486-81-9
|
| PubChem CID |
71311795
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.592
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
36
|
| Complexity |
701
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O1C([H])(C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])O[H])C1([H])C([H])([H])C1([H])C([H])([H])OC([H])(C([H])([H])C(=C([H])C(=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(=O)[O-])C([H])([H])[H])C([H])(C1([H])O[H])O[H].[Li+]
|
| InChi Key |
XFIKMPRBSORKQP-JATHGWPISA-M
|
| InChi Code |
InChI=1S/C26H44O9.Li/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);/q;+1/p-1/b16-13+;/t17-,18-,19-,20-,21-,24+,25-,26-;/m0./s1
|
| Chemical Name |
lithium;9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9741 mL | 9.8705 mL | 19.7410 mL | |
| 5 mM | 0.3948 mL | 1.9741 mL | 3.9482 mL | |
| 10 mM | 0.1974 mL | 0.9870 mL | 1.9741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
